» Articles » PMID: 12093899

Mutations in APC, Kirsten-ras, and P53--alternative Genetic Pathways to Colorectal Cancer

Overview
Specialty Science
Date 2002 Jul 3
PMID 12093899
Citations 186
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer is one of the most significant causes of cancer death. A genetic model for colorectal cancer has been proposed in which the sequential accumulation of mutations in specific genes, including adenomatous polyposis coli (APC), Kirsten-ras (K-ras), and p53, drives the transition from healthy colonic epithelia through increasingly dysplastic adenoma to colorectal cancer. We have characterized tumor mutation spectra in a large cohort of colorectal cancer patients. In marked contrast to the predictions of the sequential model of mutation accumulation, only 6.6% of tumors were found to contain mutations in APC, K-ras, and p53, with 38.7% of tumors containing mutations in only one of these genes. The most common combination of mutations was p53 and APC (27.1%), whereas mutations in both p53 and K-ras were extremely rare. Statistical analysis (two-sided Fisher's exact test) confirmed that mutations in K-ras and p53 co-occurred less frequently than expected by chance (P < 0.01, Fisher's exact test). This finding suggests that these mutations lie on alternate pathways of colorectal tumor development. The heterogeneous pattern of tumor mutations in our patient cohort suggests that multiple alternative genetic pathways to colorectal cancer exist and that the widely accepted genetic model of cancer development is not representative of the majority of colorectal tumors.

Citing Articles

Costs of Adverse Event Management Associated with First-Line Cetuximab or Panitumumab in Metastatic Colorectal Cancer Patients in Saudi Arabia.

Elsisi G, Abdul Kareem H, Alaseiri A, Alsharm A, Al Garni M, Al-Mudaiheem H J Health Econ Outcomes Res. 2025; 12(1):106-112.

PMID: 40061835 PMC: 11890290. DOI: 10.36469/001c.130878.


Unveiling the dynamics of circulating tumor cells in colorectal cancer: from biology to clinical applications.

Dompe C, Chojnowska A, Ramlau R, Nowicki M, Alix-Panabieres C, Budna-Tukan J Front Cell Dev Biol. 2024; 12:1498032.

PMID: 39539964 PMC: 11557528. DOI: 10.3389/fcell.2024.1498032.


Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations.

Weitz J, Nishizaki D, Liau J, Patel J, Ng I, Sun S J Clin Oncol. 2024; 43(6):705-715.

PMID: 39413348 PMC: 11829827. DOI: 10.1200/JCO.24.00511.


Management of Colorectal Cancer Using Nanocarriers-based Drug Delivery for Herbal Bioactives: Current and Emerging Approaches.

Deshmukh R, Prajapati M, Harwansh R Curr Pharm Biotechnol. 2024; 25(5):599-622.

PMID: 38807329 DOI: 10.2174/0113892010242028231002075512.


Delineating the mechanistic relevance of the gene and its mutational impact on gene expression and patients' survival in bladder cancer.

Chatterjee D, Heeamoni S, Sultana T, Mou S, Mostofa M, Hossain M Heliyon. 2024; 10(10):e31286.

PMID: 38803860 PMC: 11129003. DOI: 10.1016/j.heliyon.2024.e31286.


References
1.
Pretlow T, Brasitus T, Fulton N, Cheyer C, Kaplan E . K-ras mutations in putative preneoplastic lesions in human colon. J Natl Cancer Inst. 1993; 85(24):2004-7. DOI: 10.1093/jnci/85.24.2004. View

2.
Bos J . ras oncogenes in human cancer: a review. Cancer Res. 1989; 49(17):4682-9. View

3.
Brentnall T, Crispin D, Rabinovitch P, Haggitt R, RUBIN C, Stevens A . Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994; 107(2):369-78. DOI: 10.1016/0016-5085(94)90161-9. View

4.
Toribara N, Sleisenger M . Screening for colorectal cancer. N Engl J Med. 1995; 332(13):861-7. DOI: 10.1056/NEJM199503303321306. View

5.
Huang J, Papadopoulos N, McKinley A, Farrington S, Curtis L, Wyllie A . APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci U S A. 1996; 93(17):9049-54. PMC: 38593. DOI: 10.1073/pnas.93.17.9049. View